Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Gyre Therapeutics's EV/EBITDA was 231.5× on Jul 31, 2026, against 51.9× a year earlier. Over the last 4 years it ranged from 1.7× to 271.5×, with a median of 48.0×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 231.5× | +108.7 |
| 2025 | Dec 31, 2025 | 122.8× | −7.6 |
| 2024 | Jan 31, 2024 | 130.4× | −141.1 |
| 2023 | Dec 29, 2023 | 271.5× | +252.1 |
| 2022 | Dec 30, 2022 | 19.4× | −54.5 |
| 2013 | Jan 31, 2013 | 74.0× | +10.2 |
| 2012 | Dec 31, 2012 | 63.8× | +62.1 |
| 2011 | Dec 30, 2011 | 1.7× | – |
See a number that looks wrong?